Nyrada Quarterly Activities Report & Appendix 4C

Highlights:
• Cholesterol-Lowering Program:
– Charles River Laboratories appointed to conduct safety pharmacology and toxicology studies in Nyrada’s cholesterol-lowering drug in the US in 1H CY2022
– Australian world-class clinical research centre will conduct Phase I first-in-human clinical trial, set to commence in 2H CY2022
– Phase I dose escalation study will evaluate the safety, tolerability and efficacy of Nyrada’s cholesterol-lowering drug candidate
– PCT patent application filed in Dec 2021 for new generation cholesterol-lowering compounds, expanding protection of Nyrada’s PCSK9 inhibitor technology

• Brain Injury Program:
– Nyrada’s brain injury drug candidate to be tested in preclinical model of stroke in Q1 CY2022
– Pilot Traumatic Brain Injury (TBI) preclinical study under Nyrada-UNSW Sydney-WRAIR collaboration progressing well to optimise efficacy study design
– Phase I study to commence in 2H CY2022, evaluating safety and tolerability of Nyrada’s drug in two indications, TBI and stroke

• Robust cash position of A$11.1 million: R&D tax incentive rebate of A$1.3 million received in January 2022